Cooley Advises io Products on $6.5 Billion Acquisition by OpenAI
Cooley advised io Products, an engineering and product manufacturing company co-founded by Jony Ive to develop, engineer and manufacture a new family of products for the artificial general intelligence era, on its approximately $6.5 billion acquisition by OpenAI. As part of the deal, Ive and his creative collective, LoveFrom, will […]
Boston Celtics Announce $6.1 Billion Sale to Group Led by William Chisholm
Cooley advised the Boston Celtics and the Grousbeck family the majority stakeholders of Boston Basketball Partners, which owns the American professional basketball team – in connection with their agreement to sell the Celtics to an investor group led by William Chisholm. If approved, the new ownership group will buy a […]
EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca
Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis. The transaction includes an initial payment of […]
Poppi Announces $1.95 Billion Sale to PepsiCo
Cooley advised VNGR Beverage (doing business as poppi), a fast-growing prebiotic soda brand, on its acquisition by PepsiCo (Nasdaq: PEP) for $1.95 billion, including an additional potential earnout consideration subject to the achievement of certain performance milestones within a specified period after closing. Poppi Announces $1.95 Billion Sale to PepsiCo
Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical
Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash. Under the terms of the agreement, Taiho Pharmaceutical will pay Araris $400 million upfront, with the potential for additional milestone […]
DataStax Announces Acquisition by IBM
Cooley advised DataStax, an artificial intelligence (AI) and data solution provider, on its acquisition by IBM (NYSE: IBM), a provider of global hybrid cloud and AI solutions and consulting expertise. The acquisition is expected to close in Q2 of 2025, subject to customary closing conditions and regulatory approvals. DataStax Announces […]
Alani Nu’s $1.8 Billion Sale to Celsius
Cooley advised Katy Hearn and Haydn Schneider, co-founders of Alani Nutrition (Alani Nu), in connection with Celsius Holdings’ (Nasdaq: CELH) definitive agreement to acquire Alani Nu for $1.8 billion, comprising a mix of cash and stock. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to […]
Lantheus to Acquire Evergreen Theragnostics for up to $1 Billion
Cooley advised Lantheus Holdings (Nasdaq: LNTH), a radiopharmaceutical-focused company committed to enabling clinicians to find, fight and follow disease to deliver better patient outcomes, on its definitive agreement to acquire Evergreen Theragnostics. Under the terms of the agreement, Lantheus will pay an upfront amount of $250 million in cash at closing […]
Poseida Therapeutics Announces Agreement to Be Acquired by Roche for up to $1.5 Billion
Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right […]
Avid Bioservices Announces $1.1 Billion Acquisition by GHO Capital Partners and Ampersand Capital Partners
Cooley advised Avid Bioservices (Nasdaq: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high-quality development and manufacturing services to biotechnology and pharmaceutical companies, on its definitive merger agreement to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners […]